Skip NavigationSkip to Content

Remdesivir for the prevention of invasive mechanical ventilation or death in COVID-19 - A post-hoc analysis of the Adaptive COVID-19 Treatment Trial-1 Cohort Data

  1. Author:
    Paules, Catharine I
    Gallagher, Shannon K
    Rapaka, Rekha R
    Davey, Richard T
    Doernberg, Sarah B
    Grossberg, Robert
    Hynes, Noreen A
    Ponce, Philip
    Short, William R
    Voell, Jocelyn
    Wang,Jing
    Yang, Otto O
    Wolfe, Cameron R
    Lye, David C
    Dodd, Lori E
    Benson, Constance A
  2. Author Address

    Division of Infectious Diseases, Penn State Health Milton S. Hershey Medical Center, Hershey, PA, USA., Biostatistics Research Branch, National Institute of Allergy and Infectious Diseases, Rockville, MD, USA., University of Maryland Center for Vaccine Development and Global Health, University of Maryland School of Medicine, Baltimore, MD, USA., National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, MD, USA., Division of Infectious Diseases, Department of Medicine, University of California, San Francisco, San Francisco, CA, USA., Department of Medicine, Division of Infectious Diseases, Montefiore Medical Center/Albert Einstein College of Medicine, Bronx, New York, USA., Division of Infectious Diseases, Department of Medicine, Johns Hopkins University, School of Medicine, Baltimore, MD, USA., Division of Infectious Diseases, University of Texas Health San Antonio and University Health San Antonio, TX, USA., Department of Medicine, Division of Infectious Diseases, University of Pennsylvania, Philadelphia, Pennsylvania, USA., Clinical Monitoring Research Program Directorate, Frederick National Laboratory for Cancer Research, Frederick, MD, USA., Division of Infectious Diseases, Department of Medicine, David Geffen School of Medicine at University of California Los Angeles, Los Angeles, CA, USA., Department of Medicine, Infectious Disease, Duke University Medical Center, Durham, NC, USA., National Centre for Infectious Diseases; Tan Tock Seng Hospital; Yong Loo Lin School of Medicine; Lee Kong Chian School of Medicine; Singapore., Division of Infectious Diseases and Global Public Health, University of California San Diego, San Diego, CA, USA.,
    1. Year: 2021
    2. Date: Aug 11
    3. Epub Date: 2021 08 11
  1. Journal: Clinical infectious diseases : an official publication of the Infectious Diseases Society of America
  2. Type of Article: Article
  3. Article Number: ciab695
  1. Abstract:

    This post-hoc analysis of The Adaptive COVID-19 Treatment Trial-1 shows a treatment effect of remdesivir on progression to invasive mechanical ventilation (IMV) or death. Additionally, we create a risk profile that better predicts progression than baseline oxygen requirement alone. The highest risk group derives the greatest treatment effect from RDV. © The Author(s) 2021. Published by Oxford University Press for the Infectious Diseases Society of America. All rights reserved. For permissions, e-mail: journals.permissions@oup.com.

    See More

External Sources

  1. DOI: 10.1093/cid/ciab695
  2. PMID: 34379740
  3. PII : 6348134

Library Notes

  1. Fiscal Year: FY2020-2021
NCI at Frederick

You are leaving a government website.

This external link provides additional information that is consistent with the intended purpose of this site. The government cannot attest to the accuracy of a non-federal site.

Linking to a non-federal site does not constitute an endorsement by this institution or any of its employees of the sponsors or the information and products presented on the site. You will be subject to the destination site's privacy policy when you follow the link.

ContinueCancel